387 related articles for article (PubMed ID: 29280459)
61. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
[TBL] [Abstract][Full Text] [Related]
62. Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies.
Kim YJ; Kim SS; Song SY; Choi EK
Radiat Oncol; 2018 Jul; 13(1):127. PubMed ID: 29996863
[TBL] [Abstract][Full Text] [Related]
63. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
[TBL] [Abstract][Full Text] [Related]
64. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
65. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
66. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
67. Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy.
Topkan E; Yildirim BA; Guler OC; Parlak C; Pehlivan B; Selek U
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):774-80. PubMed ID: 25752391
[TBL] [Abstract][Full Text] [Related]
68. Novel chemoradiotherapy with concomitant boost thoracic radiation and concurrent cisplatin and vinorelbine for stage IIIA and IIIB non-small-cell lung cancer.
Imamura F; Konishi K; Uchida J; Nishino K; Okuyama T; Kumagai T; Kawaguchi Y; Nishiyama K
Clin Lung Cancer; 2014 Jul; 15(4):281-6. PubMed ID: 24656641
[TBL] [Abstract][Full Text] [Related]
69. Stereotactic Body Radiation Therapy for Biopsy-Proven Primary Non-Small-Cell Lung Cancer: Experience of Patients With Inoperable Cancer at a Single Brazilian Institution.
Abreu CECV; Moraes FY; Miranda FA; Siqueira GSM; Gadia R; Haddad CK; Carvalho HA
J Glob Oncol; 2018 Jul; 4():1-8. PubMed ID: 30085881
[TBL] [Abstract][Full Text] [Related]
70. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
[TBL] [Abstract][Full Text] [Related]
71. Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.
Fenwick JD; Landau DB; Baker AT; Bates AT; Eswar C; Garcia-Alonso A; Harden SV; Illsley MC; Laurence V; Malik Z; Mayles WPM; Miles E; Mohammed N; Spicer J; Wells P; Vivekanandan S; Mullin AM; Hughes L; Farrelly L; Ngai Y; Counsell N
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):733-742. PubMed ID: 31809876
[TBL] [Abstract][Full Text] [Related]
72. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
73. Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.
Temming S; Kocher M; Stoelben E; Hagmeyer L; Chang DH; Frank K; Hekmat K; Wolf J; Baus WW; Semrau R; Baues C; Marnitz S
Strahlenther Onkol; 2018 Feb; 194(2):91-97. PubMed ID: 28812120
[TBL] [Abstract][Full Text] [Related]
74. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
75. Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial.
Rimner A; Gelblum DY; Wu AJ; Shepherd AF; Mueller B; Zhang S; Cuaron J; Shaverdian N; Flynn J; Fiasconaro M; Zhang Z; von Reibnitz D; Li H; McKnight D; McCune M; Gelb E; Gomez DR; Simone CB; Deasy JO; Yorke ED; Ng KK; Chaft JE
Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):869-877. PubMed ID: 38154510
[TBL] [Abstract][Full Text] [Related]
76. Comparison of stereotactic body radiation therapy for biopsy-proven versus radiographically diagnosed early-stage non-small lung cancer: a single-institution experience.
Fischer-Valuck BW; Boggs H; Katz S; Durci M; Acharya S; Rosen LR
Tumori; 2015; 101(3):287-93. PubMed ID: 25908031
[TBL] [Abstract][Full Text] [Related]
77. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
78. Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer Database.
Brower JV; Amini A; Chen S; Hullett CR; Kimple RJ; Wojcieszynski AP; Bassetti M; Witek ME; Yu M; Harari PM; Baschnagel AM
Ann Oncol; 2016 Oct; 27(10):1887-94. PubMed ID: 27502703
[TBL] [Abstract][Full Text] [Related]
79. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
[TBL] [Abstract][Full Text] [Related]
80. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
Kong FM; Ten Haken RK; Schipper MJ; Sullivan MA; Chen M; Lopez C; Kalemkerian GP; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):324-33. PubMed ID: 16168827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
